Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified VCD Regimen in Previously Untreated Multiple Myeloma
NCT02086942Phase 2Unknown
- Start
- Aug 2013
- Primary completion
- Aug 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of bortezomib in multiple myeloma (MM) (2 arms). Primary endpoint: Complete Remission Rate. Status: unknown.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02086942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086942.